Onychomysosis
☆ Muzotsatira za 2022 Stiftung Warentest zochokera ku Germany, kukhutitsidwa kwa ogula ndi ModelDerm kunali kotsika pang'ono kusiyana ndi kuyankhulana kwa telemedicine komwe kulipiridwa.
Kukhara kukhudzidwe ndi Onychomysosis
Phazi la munthu lomwe lili ndi matenda a mafangasi a msomali patatha milungu khumi atamwa mankhwala akumwa a terbinafine. Onani gulu la kukula kwa msomali wathanzi kuseri kwa misomali yomwe ili ndi kachilombo.
References
Mankhwala antifungal ndiwothandiza kwambiri. Kusanthula kwa meta kumawonetsa machiritso a mycotic motere: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48% . Kuwonongeka kwa misomali nthawi imodzi kumawonjezera machiritso. Chithandizo chapamutu chokhala ndi ciclopirox sichithandiza; ali ndi chiwongola dzanja choposa 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Systemic antifungals are the most effective treatment. Meta-analyses shows mycotic cure rates as follows: terbinafine = 76%, itraconazole with pulse dosing = 63%, itraconazole with continuous dosing = 59%, fluconazole =48%. Concomitant nail debridement further increases cure rates. Topical therapy with ciclopirox is less effective; it has a failure rate exceeding 60%.
Onychomycosis ndi matenda a mafangasi omwe amakhudza misomali. Zikayambitsidwa ndi dermatophytes, zimatchedwa tinea unguium. Onychomycosis imaphatikizapo matenda omwe amayamba chifukwa cha dermatophytes, yisiti, ndi nkhungu. Vuto la misomali lomwe silimayambitsidwa ndi matenda oyamba ndi fungus limatchedwa nail dystrophy. Ngakhale zingakhudze zikhadabo ndi zala, toenail onychomycosis ndizofala kwambiri. Nkhaniyi ikufotokoza mbali zosiyanasiyana za toenail onychomycosis, monga momwe zimakhudzira, mitundu yazachipatala, magawo, matenda, ndi chithandizo. Ngakhale kuti sikuwopseza moyo, onychomycosis ikhoza kuyambitsa zovuta zazikulu monga cellulitis, sepsis, matenda a mafupa, kuwonongeka kwa minofu, ndi kutaya misomali.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Onychomycosis is a fungal infection of the nail unit. When dermatophytes cause onychomycosis, this condition is called tinea unguium. The term onychomycosis encompasses the dermatophytes, yeasts, and saprophytic mold infections. An abnormal nail not caused by a fungal infection is a dystrophic nail. Onychomycosis can infect both fingernails and toenails, but onychomycosis of the toenail is much more prevalent. Discussed in detail in this activity are all evolving facets of the topic, including disease burden, clinical types, staging, diagnosis, and management of toenail onychomycosis. While non-life-threatening, onychomycosis can lead to severe complications such as cellulitis, sepsis, osteomyelitis, tissue damage, and nail loss.
Terbinafine ndi mankhwala omwe amalimbana ndi matenda oyamba ndi fungus potsekereza squalene epoxidase. Ndiwothandiza polimbana ndi mitundu yambiri ya mafangasi apakhungu ndipo ndi ovomerezeka kuchiza mafangasi akamatengedwa pakamwa. Ngakhale zotsatira zoyipa zambiri monga kupweteka kwa mutu ndi m'mimba zimakhala zazing'ono ndipo zimapita zokha, kusintha kwa kukoma (dysgeusia) kumasiyana kuchokera ku kufewa mpaka koopsa, nthawi zina kumayambitsa kuwonda. Kusintha kosatha kwa kukoma kumakhala kosowa koma kwanenedwa.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Terbinafine is an antifungal medication that works through the inhibition of squalene epoxidase. It has activity against most dermatophytes, and it has approval for use as an oral therapy for the treatment of onychomycosis. Although most side effects are mild and self-limited, such as headache and gastrointestinal symptoms, taste disturbances (dysgeusia) can range from mild to severe, resulting in weight loss, and have rarely been reported permanent.
Onychomycosis ndi matenda a mafangasi omwe amakhudza misomali. Pafupifupi 90% ya matenda a zikhadabo ndi 75% ya matenda a zikhadabo amayamba ndi bowa (Trichophyton mentagrophytes, Trichophyton rubrum) . Zizindikiro zake ndi kusinthika kwa misomali, kukhuthala, kupatukana ndi bedi la misomali, komanso kukulirakulira. Chithandizo nthawi zambiri chimaphatikizapo kumwa mankhwala amkamwa monga terbinafine kapena itraconazole, ndipo chithandizo chapakhungu chimakhala chotheka kwa odwala omwe ali ochepa kapena ochepa.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Onychomycosis is a fungal infection of the nail unit. Approximately 90% of toenail and 75% of fingernail onychomycosis are caused by dermatophytes, notably Trichophyton mentagrophytes and Trichophyton rubrum. Clinical manifestations include discoloration of the nail, subungual hyperkeratosis, onycholysis, and onychauxis. Currently, oral terbinafine is the treatment of choice, followed by oral itraconazole. In general, topical monotherapy can be considered for mild to moderate onychomycosis.
Mankhwala a antifungal terbinafine omwe amatengedwa pakamwa akuwoneka kuti ndi othandiza kwambiri koma terbinafine amalumikizidwa ndi zotsatira za chiwindi.
Onychomysosis amapezeka pafupifupi 10 peresenti ya anthu akuluakulu, ndipo okalamba amakhudzidwa kwambiri. Amuna amakhudzidwa nthawi zambiri kuposa akazi. Onychomysosis imayimira pafupifupi theka la matenda a misomali. Izi zikutanthauza kuti kupunduka kwa toenails kungabwerenso ku zifukwa zina osati onychomycosis.
○ Kuchiza - Mankhwala OTC
Ndizovuta kuchiza onychomycosis ndi mankhwala apakhungu chifukwa ndizovuta kuti mankhwala alowe mu zikhadabo zokhuthala.
#Ketoconazole
#Clotrimazole
#Miconazole
#Terbinafine
#Butenafine [Lotrimin]
#Tolnaftate
○ Machiritso
Chithandizo cha nthawi yayitali nthawi zambiri chimafunikira mpaka chipolopolo cha kachilomboka chachotsedwa kwathunthu.
#Terbinafine (oral)
#Itraconazole
#Efinaconazole lacquer [Jublia]
#Ciclopirox lacquer